Sepracor Soltara “not approvable”
Executive Summary
Sepracor's NDA for allergic rhinitisproduct Soltara (tecastemizole) deemed "not approvable" March 6. FDA wants additional assurance that there is no potential for QTc prolongation with the product. FDA also raised issues related to phospholipidosis and cardiomyopathy observed in animal safety studies. The Soltara NDA was submitted March 9, 2001. Soltara is a metabolite of Janssen's Hismanal (astemizole), which was removed from the market in 1999 due to cardiac side effects...
You may also be interested in...
FDA Phospholipidosis Guidance Being Developed; Toxicity Is Concern
FDA is planning to develop a guidance on phospholipidosis issues in drug products
Sepracor discontinues Soltara
Sepracor discontinues development of allergic rhinitis treatment Soltara (tecastemizole). FDA issued "not approvable" letter in March 2002, citing insufficient evidence concerning QTc interval prolongation (1"The Pink Sheet" March, 11, 2002, In Brief)...
Sepracor Estorra NDA Filing Planned By Mid-Feb.; Xopenex MDI By Year-End
Sepracor is planning an NDA filing for its sleep disorder drug Estorra by Feb. 15, followed by a submission for its Xopenex metered dose inhaler formulation before year-end